Antibacterial agent 318 

Antibacterial agent 318 is an antibacterial agent that binds to bacterial DNA, blocks its replication, and forms supramolecular complexes. Antibacterial agent 318 acts as an oxidative stress inducer, elevating intracellular reactive oxygen species (ROS) levels, oxidizing glutathione (GSH) to glutathione disulfide (GSSG), depleting cellular GSH reserves, and inducing bacterial cell death through oxidative damage. Antibacterial agent 318 disrupts the bacterial cell membrane and reduces bacterial metabolic activity. Antibacterial agent 318 exhibits rapid bactericidal activity, inhibits bacterial biofilm formation, and displays minimal cytotoxicity toward non-cancerous mammalian cells. Antibacterial agent 318 is applicable in research on drug-resistant bacterial infections^[1].

Antibacterial agent 318 (compound 12f) 可抑制粪肠球菌 (E. faecalis) 、乳杆菌属 (L. species) 、枯草芽孢杆菌 (B. subtilis) 、金黄色葡萄球菌 (S. aureus) 、大肠杆菌 (E. coli) 和粘质沙雷氏菌 (S. marcescens) 的生长，其 MIC 值范围为 1.56 至 6.25 μg/mL^[1]。
Antibacterial agent 318 (1.56-12.48 μg/mL；2.5-5 h) 对 E. faecalis 表现出快速杀菌活性：在 1× MIC 浓度下可于 5 小时内杀灭细菌，在 8× MIC 浓度下可于 3.5 小时内杀灭细菌；与 Tetracycline (HY-A0107) 联用时具有协同快速杀灭作用 (2.5 小时) ^[1]。
Antibacterial agent 318 (1.56-12.48 μg/mL) 可以浓度依赖的方式抑制 E. faecalis 生物膜的形成和自聚集，在 8× MIC 时可使生物膜形成率降低 83%^[1]。
Antibacterial agent 318 (1.56-12.48 μg/mL) 在 1× MIC 时可使 E. faecalis 的 EPS 含量降低 69.7%，在 8× MIC 时降低 74.4%^[1]。
Antibacterial agent 318 (30 μM) 对 HEK293 细胞表现出极低的细胞毒性，在 30 μM 浓度下细胞存活率高于 87%^[1]。
Antibacterial agent 318 (1.56 μg/mL) 在 1× MIC 浓度下会对 E. faecalis (粪肠球菌) 细胞造成严重的形态损伤，包括细胞壁破裂和细胞质渗漏^[1]。
Antibacterial agent 318 (1.56-12.48 μg/mL) 可在粪肠球菌 (E. faecalis) 中诱导代谢停滞，以浓度依赖的方式诱导粪肠球菌 (E. faecalis) 产生细胞内活性氧 (ROS)，并降低 GSH 活性；还可诱导脂质过氧化，在 8× MIC浓度下使 MDA 水平升高至 6 倍^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

611.67

C₃₅H₂₅N₅O₄S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jain A, et al. Unravelling the antibacterial potential and mechanistic insights of spirocyclic naphthalimide analogues against drug-resistant bacteria. Eur J Med Chem. 2026;304:118530.  [Content Brief]